BAUSCH + LOMB CORP (BLCO) Stock Fundamental Analysis

NYSE:BLCO • CA0717051076

17.03 USD
+0.3 (+1.79%)
At close: Feb 13, 2026
17.03 USD
0 (0%)
After Hours: 2/13/2026, 8:04:00 PM
Fundamental Rating

3

Taking everything into account, BLCO scores 3 out of 10 in our fundamental rating. BLCO was compared to 185 industry peers in the Health Care Equipment & Supplies industry. While BLCO is still in line with the averages on profitability rating, there are concerns on its financial health. BLCO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • BLCO had positive earnings in the past year.
  • In the past year BLCO had a positive cash flow from operations.
  • In multiple years BLCO reported negative net income over the last 5 years.
  • Of the past 5 years BLCO 4 years had a positive operating cash flow.
BLCO Yearly Net Income VS EBIT VS OCF VS FCFBLCO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

  • BLCO has a Return On Assets of -2.21%. This is in the better half of the industry: BLCO outperforms 69.89% of its industry peers.
  • With a decent Return On Equity value of -4.74%, BLCO is doing good in the industry, outperforming 70.43% of the companies in the same industry.
  • BLCO has a better Return On Invested Capital (0.77%) than 66.13% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for BLCO is significantly below the industry average of 8.77%.
Industry RankSector Rank
ROA -2.21%
ROE -4.74%
ROIC 0.77%
ROA(3y)-1.41%
ROA(5y)-0.54%
ROE(3y)-2.87%
ROE(5y)-1.37%
ROIC(3y)1.59%
ROIC(5y)1.92%
BLCO Yearly ROA, ROE, ROICBLCO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 2 -2 -4

1.3 Margins

  • BLCO's Operating Margin of 2.33% is fine compared to the rest of the industry. BLCO outperforms 67.20% of its industry peers.
  • In the last couple of years the Operating Margin of BLCO has declined.
  • BLCO has a Gross Margin of 59.45%. This is in the better half of the industry: BLCO outperforms 60.22% of its industry peers.
  • In the last couple of years the Gross Margin of BLCO has remained more or less at the same level.
Industry RankSector Rank
OM 2.33%
PM (TTM) N/A
GM 59.45%
OM growth 3Y-22.07%
OM growth 5Y-17.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-1.25%
BLCO Yearly Profit, Operating, Gross MarginsBLCO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

1

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BLCO is destroying value.
  • The number of shares outstanding for BLCO has been increased compared to 1 year ago.
  • Compared to 5 years ago, BLCO has more shares outstanding
  • The debt/assets ratio for BLCO is higher compared to a year ago.
BLCO Yearly Shares OutstandingBLCO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 100M 200M 300M
BLCO Yearly Total Debt VS Total AssetsBLCO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • Based on the Altman-Z score of 0.87, we must say that BLCO is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 0.87, BLCO is in line with its industry, outperforming 52.69% of the companies in the same industry.
  • A Debt/Equity ratio of 0.77 indicates that BLCO is somewhat dependend on debt financing.
  • The Debt to Equity ratio of BLCO (0.77) is worse than 69.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Altman-Z 0.87
ROIC/WACC0.07
WACC10.37%
BLCO Yearly LT Debt VS Equity VS FCFBLCO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 1.51 indicates that BLCO should not have too much problems paying its short term obligations.
  • BLCO's Current ratio of 1.51 is on the low side compared to the rest of the industry. BLCO is outperformed by 73.66% of its industry peers.
  • A Quick Ratio of 0.98 indicates that BLCO may have some problems paying its short term obligations.
  • With a Quick ratio value of 0.98, BLCO is not doing good in the industry: 76.34% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.98
BLCO Yearly Current Assets VS Current LiabilitesBLCO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

3

3. Growth

3.1 Past

  • The earnings per share for BLCO have decreased strongly by -29.51% in the last year.
  • The Revenue has been growing slightly by 6.23% in the past year.
  • Measured over the past years, BLCO shows a small growth in Revenue. The Revenue has been growing by 4.87% on average per year.
EPS 1Y (TTM)-29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.88%
Revenue 1Y (TTM)6.23%
Revenue growth 3Y8.36%
Revenue growth 5Y4.87%
Sales Q2Q%7.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.96% on average over the next years. This is quite good.
  • BLCO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.49% yearly.
EPS Next Y-10.8%
EPS Next 2Y13.94%
EPS Next 3Y20.44%
EPS Next 5Y19.96%
Revenue Next Year6.46%
Revenue Next 2Y6.14%
Revenue Next 3Y5.92%
Revenue Next 5Y5.49%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BLCO Yearly Revenue VS EstimatesBLCO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
BLCO Yearly EPS VS EstimatesBLCO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

3

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 39.60, which means the current valuation is very expensive for BLCO.
  • Based on the Price/Earnings ratio, BLCO is valued a bit cheaper than the industry average as 70.97% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.68. BLCO is valued slightly more expensive when compared to this.
  • Based on the Price/Forward Earnings ratio of 21.16, the valuation of BLCO can be described as rather expensive.
  • BLCO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BLCO is cheaper than 79.03% of the companies in the same industry.
  • BLCO's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 28.06.
Industry RankSector Rank
PE 39.6
Fwd PE 21.16
BLCO Price Earnings VS Forward Price EarningsBLCO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, BLCO is valued a bit cheaper than 75.27% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 19.62
BLCO Per share dataBLCO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • BLCO's earnings are expected to grow with 20.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.94%
EPS Next 3Y20.44%

0

5. Dividend

5.1 Amount

  • BLCO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

BAUSCH + LOMB CORP

NYSE:BLCO (2/13/2026, 8:04:00 PM)

After market: 17.03 0 (0%)

17.03

+0.3 (+1.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-29
Earnings (Next)02-18
Inst Owners11.05%
Inst Owner Change-93.92%
Ins Owners0.45%
Ins Owner Change0.1%
Market Cap6.03B
Revenue(TTM)4.98B
Net Income(TTM)-305.00M
Analysts72.63
Price Target17.68 (3.82%)
Short Float %9.56%
Short Ratio11.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.13%
Min EPS beat(2)1.79%
Max EPS beat(2)8.47%
EPS beat(4)3
Avg EPS beat(4)-86.5%
Min EPS beat(4)-360.35%
Max EPS beat(4)8.47%
EPS beat(8)6
Avg EPS beat(8)-37.66%
EPS beat(12)9
Avg EPS beat(12)-24.06%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.15%
Min Revenue beat(2)-1.91%
Max Revenue beat(2)-0.39%
Revenue beat(4)0
Avg Revenue beat(4)-1.38%
Min Revenue beat(4)-3.07%
Max Revenue beat(4)-0.16%
Revenue beat(8)3
Avg Revenue beat(8)0.21%
Revenue beat(12)6
Avg Revenue beat(12)0.82%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.96%
PT rev (3m)14.6%
EPS NQ rev (1m)-3.3%
EPS NQ rev (3m)-5.77%
EPS NY rev (1m)0.21%
EPS NY rev (3m)0.88%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.14%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
Industry RankSector Rank
PE 39.6
Fwd PE 21.16
P/S 1.21
P/FCF N/A
P/OCF 35.7
P/B 0.94
P/tB N/A
EV/EBITDA 19.62
EPS(TTM)0.43
EY2.52%
EPS(NY)0.8
Fwd EY4.73%
FCF(TTM)-0.55
FCFYN/A
OCF(TTM)0.48
OCFY2.8%
SpS14.04
BVpS18.15
TBVpS-4.39
PEG (NY)N/A
PEG (5Y)N/A
Graham Number13.25
Profitability
Industry RankSector Rank
ROA -2.21%
ROE -4.74%
ROCE 0.97%
ROIC 0.77%
ROICexc 0.79%
ROICexgc 2.52%
OM 2.33%
PM (TTM) N/A
GM 59.45%
FCFM N/A
ROA(3y)-1.41%
ROA(5y)-0.54%
ROE(3y)-2.87%
ROE(5y)-1.37%
ROIC(3y)1.59%
ROIC(5y)1.92%
ROICexc(3y)1.64%
ROICexc(5y)1.97%
ROICexgc(3y)5.47%
ROICexgc(5y)6.76%
ROCE(3y)2.02%
ROCE(5y)2.43%
ROICexgc growth 3Y-21.86%
ROICexgc growth 5Y-17.06%
ROICexc growth 3Y-20.45%
ROICexc growth 5Y-15.79%
OM growth 3Y-22.07%
OM growth 5Y-17.92%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.06%
GM growth 5Y-1.25%
F-Score4
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.77
Debt/FCF N/A
Debt/EBITDA 9.05
Cap/Depr 85.28%
Cap/Sales 7.34%
Interest Coverage 250
Cash Conversion 31.07%
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 0.98
Altman-Z 0.87
F-Score4
WACC10.37%
ROIC/WACC0.07
Cap/Depr(3y)53.43%
Cap/Depr(5y)52.81%
Cap/Sales(3y)5.03%
Cap/Sales(5y)5.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.51%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.88%
EPS Next Y-10.8%
EPS Next 2Y13.94%
EPS Next 3Y20.44%
EPS Next 5Y19.96%
Revenue 1Y (TTM)6.23%
Revenue growth 3Y8.36%
Revenue growth 5Y4.87%
Sales Q2Q%7.11%
Revenue Next Year6.46%
Revenue Next 2Y6.14%
Revenue Next 3Y5.92%
Revenue Next 5Y5.49%
EBIT growth 1Y-38.95%
EBIT growth 3Y-15.55%
EBIT growth 5Y-13.93%
EBIT Next Year46.23%
EBIT Next 3Y23.51%
EBIT Next 5Y15.82%
FCF growth 1Y-880%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y33.07%
OCF growth 3Y-35.71%
OCF growth 5Y-21.91%

BAUSCH + LOMB CORP / BLCO FAQ

What is the fundamental rating for BLCO stock?

ChartMill assigns a fundamental rating of 3 / 10 to BLCO.


What is the valuation status of BAUSCH + LOMB CORP (BLCO) stock?

ChartMill assigns a valuation rating of 3 / 10 to BAUSCH + LOMB CORP (BLCO). This can be considered as Overvalued.


Can you provide the profitability details for BAUSCH + LOMB CORP?

BAUSCH + LOMB CORP (BLCO) has a profitability rating of 4 / 10.


What is the financial health of BAUSCH + LOMB CORP (BLCO) stock?

The financial health rating of BAUSCH + LOMB CORP (BLCO) is 1 / 10.